WealthPlan Investment Management LLC Sells 2,176 Shares of Amgen Inc. $AMGN

WealthPlan Investment Management LLC decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 5.4% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 38,131 shares of the medical research company’s stock after selling 2,176 shares during the period. WealthPlan Investment Management LLC’s holdings in Amgen were worth $10,761,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Wealth Quarterback LLC grew its stake in shares of Amgen by 1.6% during the third quarter. Wealth Quarterback LLC now owns 2,210 shares of the medical research company’s stock valued at $624,000 after buying an additional 34 shares during the last quarter. Fairvoy Private Wealth LLC raised its holdings in Amgen by 1.1% in the second quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company’s stock worth $885,000 after purchasing an additional 35 shares in the last quarter. Nicholson Wealth Management Group LLC lifted its holdings in shares of Amgen by 0.6% during the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company’s stock valued at $1,652,000 after purchasing an additional 35 shares during the last quarter. LS Investment Advisors LLC raised its position in shares of Amgen by 4.1% in the 3rd quarter. LS Investment Advisors LLC now owns 885 shares of the medical research company’s stock worth $250,000 after purchasing an additional 35 shares during the last quarter. Finally, Crown Wealth Group LLC lifted its position in Amgen by 4.0% in the 3rd quarter. Crown Wealth Group LLC now owns 910 shares of the medical research company’s stock valued at $257,000 after acquiring an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 3,139 shares of the company’s stock in a transaction dated Thursday, November 20th. The stock was sold at an average price of $337.26, for a total value of $1,058,659.14. Following the sale, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.69% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Scotiabank initiated coverage on shares of Amgen in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price for the company. UBS Group raised shares of Amgen to a “strong-buy” rating in a report on Wednesday, January 7th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Daiwa Capital Markets lifted their price target on shares of Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating on shares of Amgen in a report on Tuesday, November 25th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and a consensus price target of $338.55.

Amgen Price Performance

AMGN stock opened at $324.30 on Wednesday. The company has a 50 day simple moving average of $330.88 and a 200 day simple moving average of $305.32. The stock has a market cap of $174.63 billion, a price-to-earnings ratio of 25.06, a P/E/G ratio of 2.97 and a beta of 0.45. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $346.38. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.Amgen’s revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the company earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date is Friday, February 13th. This represents a $10.08 annualized dividend and a yield of 3.1%. Amgen’s dividend payout ratio is currently 73.57%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.